Literature DB >> 27101794

Melatonin inhibits the sphingosine kinase 1/sphingosine-1-phosphate signaling pathway in rabbits with fulminant hepatitis of viral origin.

Irene Crespo1,2, Beatriz San-Miguel1,2, Diana I Sánchez1, Bárbara González-Fernández1, Marcelino Álvarez3, Javier González-Gallego1,2, María J Tuñón1,2.   

Abstract

The sphingosine kinase (SphK)1/sphingosine-1-phosphate (S1P) pathway is involved in multiple biological processes, including liver diseases. This study investigate whether modulation of the SphK1/S1P system associates to the beneficial effects of melatonin in an animal model of acute liver failure (ALF) induced by the rabbit hemorrhagic disease virus (RHDV). Rabbits were experimentally infected with 2 × 10(4) hemagglutination units of a RHDV isolate and received 20 mg/kg of melatonin at 0, 12, and 24 hr postinfection. Liver mRNA levels, protein concentration, and immunohistochemical labeling for SphK1 increased in RHDV-infected rabbits. S1P production and protein expression of the S1PR1 receptor were significantly elevated following RHDV infection. These effects were significantly reduced by melatonin. Rabbits also exhibited increased expression of toll-like receptor (TLR)4, tumor necrosis factor alpha (TNF-α), interleukin (IL)-6, nuclear factor-kappa B (NF-κB) p50 and p65 subunits, and phosphorylated inhibitor of kappa B (IκB)α. Melatonin administration significantly inhibited those changes and induced a decreased immunoreactivity for RHDV viral VP60 antigen in the liver. Results obtained indicate that the SphK1/S1P system activates in parallel to viral replication and the inflammatory process induced by the virus. Inhibition of the lipid signaling pathway by the indole reveals novel molecular pathways that may account for the protective effect of melatonin in this animal model of ALF, and supports the potential of melatonin as an antiviral agent.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  acute liver failure; liver; melatonin; sphingosine kinase 1; sphingosine-1-phosphate

Mesh:

Substances:

Year:  2016        PMID: 27101794     DOI: 10.1111/jpi.12335

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  16 in total

Review 1.  Sphingosine kinase and sphingosine-1-phosphate in liver pathobiology.

Authors:  Timothy Rohrbach; Michael Maceyka; Sarah Spiegel
Journal:  Crit Rev Biochem Mol Biol       Date:  2017-06-15       Impact factor: 8.250

Review 2.  SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19.

Authors:  Ana Muñoz-Jurado; Begoña M Escribano; Eduardo Agüera; Javier Caballero-Villarraso; Alberto Galván; Isaac Túnez
Journal:  J Neurol       Date:  2022-07-05       Impact factor: 6.682

Review 3.  Melatonin for the treatment of sepsis: the scientific rationale.

Authors:  Ruben Manuel Luciano Colunga Biancatelli; Max Berrill; Yassen H Mohammed; Paul E Marik
Journal:  J Thorac Dis       Date:  2020-02       Impact factor: 2.895

Review 4.  Melatonin and Fertoprotective Adjuvants: Prevention against Premature Ovarian Failure during Chemotherapy.

Authors:  Hoon Jang; Kwonho Hong; Youngsok Choi
Journal:  Int J Mol Sci       Date:  2017-06-07       Impact factor: 5.923

5.  Protective Effect of Protocatechuic Acid on TNBS-Induced Colitis in Mice Is Associated with Modulation of the SphK/S1P Signaling Pathway.

Authors:  Irene Crespo; Beatriz San-Miguel; José Luis Mauriz; Juan José Ortiz de Urbina; Mar Almar; María Jesús Tuñón; Javier González-Gallego
Journal:  Nutrients       Date:  2017-03-16       Impact factor: 5.717

Review 6.  The wide utility of rabbits as models of human diseases.

Authors:  Pedro J Esteves; Joana Abrantes; Hanna-Mari Baldauf; Lbachir BenMohamed; Yuxing Chen; Neil Christensen; Javier González-Gallego; Lorenzo Giacani; Jiafen Hu; Gilla Kaplan; Oliver T Keppler; Katherine L Knight; Xiang-Peng Kong; Dennis K Lanning; Jacques Le Pendu; Ana Lemos de Matos; Jia Liu; Shuying Liu; Ana M Lopes; Shan Lu; Sheila Lukehart; Yukari C Manabe; Fabiana Neves; Grant McFadden; Ruimin Pan; Xuwen Peng; Patricia de Sousa-Pereira; Ana Pinheiro; Masmudur Rahman; Natalie Ruvoën-Clouet; Selvakumar Subbian; Maria Jesús Tuñón; Wessel van der Loo; Michael Vaine; Laura E Via; Shixia Wang; Rose Mage
Journal:  Exp Mol Med       Date:  2018-05-22       Impact factor: 8.718

Review 7.  Melatonin in Early Treatment for COVID-19: A Narrative Review of Current Evidence and Possible Efficacy.

Authors:  Kristina M Cross; Dylan M Landis; Laveena Sehgal; J Drew Payne
Journal:  Endocr Pract       Date:  2021-06-10       Impact factor: 3.443

Review 8.  Sphingosine 1-Phosphate Signaling as a Target in Hepatic Fibrosis Therapy.

Authors:  Bárbara González-Fernández; Diana I Sánchez; Javier González-Gallego; María J Tuñón
Journal:  Front Pharmacol       Date:  2017-08-25       Impact factor: 5.810

9.  Melatonin modulates mitophagy, innate immunity and circadian clocks in a model of viral-induced fulminant hepatic failure.

Authors:  Irene Crespo; Paula Fernández-Palanca; Beatriz San-Miguel; Marcelino Álvarez; Javier González-Gallego; María Jesús Tuñón
Journal:  J Cell Mol Med       Date:  2020-05-29       Impact factor: 5.310

Review 10.  Pharmacological agents under investigation in the treatment of coronavirus disease 2019 and the importance of melatonin.

Authors:  Hakan Parlakpinar; Seyhan Polat; Haci Ahmet Acet
Journal:  Fundam Clin Pharmacol       Date:  2020-10-14       Impact factor: 2.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.